SCHEMBL27218663

SCHEMBL27218663

Cc1cc(N)nc(SCc2nnc(-c3ccc(F)cc3)o2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.62
▸ ALDH1A1 P00352 3/20 0.62
▸ SMN1; SMN2 Q16637 6/20 0.51
▸ HPGD P15428 4/20 0.48
▸ DCK P27707 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ USP2 O75604 3/20 0.48
▸ POLB P06746 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MITF O75030 1/20 0.45
▸ MAPT P10636 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218873 0.91 SMN1; SMN2 (0.55) LMNAALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL27218853 0.88 SMN1; SMN2 (0.60) LMNAALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL31494405 0.88 HSD17B10 (0.58) LMNAALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL27218684 0.87 NPSR1 (0.51) LMNAALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL27218752 0.84 LMNA (0.50) LMNAALDH1A1SMN1; SMN2HPGDDCK
SCHEMBL31494314 0.81 HPGD (0.47) LMNAALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL27218919 0.81 HPGD (0.47) LMNAALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL27218845 0.81 ALDH1A1 (0.49) LMNAALDH1A1SMN1; SMN2HPGDDCK
SCHEMBL31494346 0.81 ALDH1A1 (0.49) LMNAALDH1A1SMN1; SMN2HPGDDCK
SCHEMBL27218744 0.80 KDM4E (0.53) LMNAALDH1A1SMN1; SMN2HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 LMNA 3526/4885ALDH1A1 1767/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback